Amyotrophic Lateral Sclerosis Agents - Antioxidants

Amyotrophic lateral sclerosis (ALS) agents classified as antioxidants—most notably edaravone—are neuroprotective therapies primarily indicated to slow the progression of physical functional decline in adults diagnosed with ALS While the specific phrase frequently serves as a compendial or formulary therapeutic grouping rather than a standalone standard ontology, its recognized clinical application remains targeted to ALS management

Amyotrophic lateral sclerosis (ALS) agents classified as antioxidants—most notably edaravone—are neuroprotective therapies primarily indicated to slow the progression of physical functional decline in adults diagnosed with ALS Although the precise clinical mechanism of action remains incompletely defined, these agents function by scavenging reactive oxygen species and reducing lipid peroxidation, thereby mitigating oxidative-stress-induced cellular damage and motor neuron degeneration in the bra...

Amyotrophic lateral sclerosis (ALS) agents classified as antioxidants—most notably edaravone—are neuroprotective therapies primarily indicated to slow the progression of physical functional decline in adults diagnosed with ALS While the specific phrase frequently serves as a compendial or formulary therapeutic grouping rather than a standalone standard ontology, its recognized clinical application remains targeted to ALS management

Although the precise clinical mechanism of action remains incompletely defined, these agents function by scavenging reactive oxygen species and reducing lipid peroxidation, thereby mitigating oxidative-stress-induced cellular damage and motor neuron degeneration in the brain and spinal cord

Although the precise clinical mechanism of action remains incompletely defined, these agents function by scavenging reactive oxygen species and reducing lipid peroxidation, thereby mitigating oxidative-stress-induced cellular damage and motor neuron degeneration in the brain and spinal cord